Clinical Trial: NCT02176967 - My Cancer Genome

NCT02176967

Description:

This phase III trial studies how well response and biology-based risk factor-guided therapy works in treating younger patients with non-high risk neuroblastoma. Sometimes a tumor may not need treatment until it progresses. In this case, observation may be sufficient. Measuring biomarkers in tumor cells may help plan when effective treatment is necessary and what the best treatment is. Response and biology-based risk factor-guided therapy may be effective in treating patients with non-high risk neuroblastoma and may help to avoid some of the risks and side effects related to standard treatment.

Related Conditions:

Ganglioneuroblastoma
Neuroblastoma

Recruiting Status:

Recruiting

Phase:

Phase 3

URL:

https://clinicaltrials.gov/show/NCT02176967

Trial Eligibility

Document

Title

Brief Title: Response and Biology-Based Risk Factor-Guided Therapy in Treating Younger Patients With Non-high Risk Neuroblastoma
Official Title: Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients With Non-High-Risk Neuroblastoma

Clinical Trial IDs

ORG STUDY ID: ANBL1232
SECONDARY ID: NCI-2014-00677
SECONDARY ID: s15-00462
SECONDARY ID: ANBL1232
SECONDARY ID: ANBL1232
SECONDARY ID: U10CA180886
SECONDARY ID: U10CA098543
NCT ID: NCT02176967

Conditions

Ganglioneuroblastoma
Localized Resectable Neuroblastoma
Localized Unresectable Neuroblastoma
Neuroblastoma

Interventions

Drug	Synonyms	Arms
Carboplatin	Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo	Group B (clinical observation, first-line chemotherapy)
Cyclophosphamide	(-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719	Group B (clinical observation, first-line chemotherapy)
Doxorubicin Hydrochloride	5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8, 9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride, (8S-cis)- (9CI), ADM, Adriacin, Adriamycin, Adriamycin Hydrochloride, Adriamycin PFS, Adriamycin RDF, ADRIAMYCIN, HYDROCHLORIDE, Adriamycine, Adriblastina, Adriblastine, Adrimedac, Chloridrato de Doxorrubicina, DOX, DOXO-CELL, Doxolem, Doxorubicin HCl, Doxorubicin.HCl, Doxorubin, Farmiblastina, FI 106, FI-106, hydroxydaunorubicin, Rubex	Group B (clinical observation, first-line chemotherapy)
Etoposide	Demethyl Epipodophyllotoxin Ethylidine Glucoside, EPEG, Lastet, Toposar, Vepesid, VP 16, VP 16-213, VP-16, VP-16-213, VP16	Group B (clinical observation, first-line chemotherapy)

Purpose

Detailed Description

      PRIMARY OBJECTIVES:

      I. To eliminate therapy as the initial approach for infants < 12 months of age with small
      International Neuroblastoma Risk Group (INRG) stage L1 neuroblastoma while maintaining an
      overall survival (OS) of 99%.

      II. To eliminate therapy as the initial approach for non-high-risk patients < 18 months of
      age with localized neuroblastoma and favorable biology (histologic and genomic features)
      while maintaining an OS of 99%.

      III. To achieve a 3-year OS of > 81% for infants < 18 months of age with INRG stage Ms
      neuroblastoma using objective criteria for early initiation of a response-based treatment
      algorithm.

      EXPLORATORY OBJECTIVES:

      I. To describe the time to intervention or tumor progression, type of intervention and site
      of progression for patients with localized neuroblastoma who experience progression after an
      initial period of observation.

      II. To characterize the pharmacokinetic profile of the chemotherapeutic agents carboplatin
      and etoposide in patients with stage Ms disease.

      III. To define the genomic profile of tumors from patients with non-high-risk neuroblastoma
      both at initial biopsy and at the time of subsequent biopsy or surgical resection.

      IV. To describe the histology of tumor specimens obtained at the time of subsequent biopsy or
      surgical resection.

      V. To determine the salvage rate (OS) of patients with tumor relapse or disease progression.

      VI. To determine the procedural complication rate (initial biopsy, resection [intraoperative
      and postoperative], subsequent biopsy) and correlate with the degree of surgical resection.

      VII. To determine the rate of reduction in image defined risk factors (IDRF) in L2 tumors
      following observation or chemotherapy.

      OUTLINE: Patients are assigned to 1 of 3 treatment groups.

      GROUP A: Patients undergo clinical observation for 96 weeks in the absence disease
      progression.

      GROUP B: Patients undergo clinical observation for 3 years in the absence of disease
      progression. Upon disease progression, patients undergo surgery or receive first-line
      chemotherapy comprising carboplatin intravenously (IV) over 1 hour on day 1 (courses 1, 2, 4,
      6, and 7), etoposide IV over 1 hour on days 1-3 (courses 1, 3, 4, 5, and 7), cyclophosphamide
      IV over 1 hour on day 1 (courses 2, 3, 5, 6, and 8), and doxorubicin hydrochloride IV over 15
      minutes on day 1 (courses 2, 4, 6 and 8). Treatment with chemotherapy repeats every 21 days
      for 2-8 courses in the absence of disease progression or unacceptable toxicity. Once a
      partial response (PR) or better is achieved, patients undergo clinical observation for 3
      years.

      GROUP C: Patients at high risk for deterioration and a poor outcome immediately receive
      first-line chemotherapy as in Group B. All other patients undergo clinical observation for 3
      years in the absence of disease progression. Upon disease progression, patients receive
      first-line chemotherapy as in Group B. Once a PR or better is achieved, patients undergo
      clinical observation for 3 years.

      After completion of study treatment, patients are followed up annually for up to 10 years
      post-enrollment.

Trial Arms

Name	Type	Description	Interventions
Group A (clinical observation)	Experimental	Patients undergo clinical observation for 96 weeks in the absence of disease progression.
Group B (clinical observation, first-line chemotherapy)	Experimental	Patients undergo clinical observation for 3 years in the absence of disease progression. Upon disease progression, patients undergo surgery or receive first-line chemotherapy comprising carboplatin IV over 1 hour on day 1 (courses 1, 2, 4, 6, and 7), etoposide IV over 1 hour on days 1-3 (courses 1, 3, 4, 5, and 7), cyclophosphamide IV over 1 hour on day 1 (courses 2, 3, 5, 6, and 8), and doxorubicin hydrochloride IV over 15 minutes on day 1 (courses 2, 4, 6 and 8). Treatment with chemotherapy repeats every 21 days for 2-8 courses in the absence of disease progression or unacceptable toxicity. Once a PR or better is achieved, patients undergo clinical observation for 3 years.	Carboplatin Cyclophosphamide Doxorubicin Hydrochloride Etoposide
Group C (clinical observation, first-line chemotherapy)	Experimental	Patients at high risk for deterioration and a poor outcome immediately receive first-line chemotherapy as in Group B. All other patients undergo clinical observation for 3 years in the absence of disease progression. Upon disease progression, patients receive first-line chemotherapy as in Group B. Once a PR or better is achieved, patients undergo clinical observation for 3 years.	Carboplatin Cyclophosphamide Doxorubicin Hydrochloride Etoposide

Eligibility Criteria

        Inclusion Criteria:

          -  Patients must be:

               -  < 12 months (< 365 days) of age at diagnosis with INRG stage L1; or

               -  < 18 months (< 547 days) of age at diagnosis with INRG stage L2 or stage Ms
                  neuroblastoma/ganglioneuroblastoma

          -  Enrollment on ANBL00B1 or APEC14B1 is required for all newly diagnosed patients

          -  Patients must have newly diagnosed v-myc avian myelocytomatosis viral oncogene
             neuroblastoma derived homolog (MYCN) non-amplified neuroblastoma (International
             Classification of Diseases for Oncology [ICD-O] morphology 9500/3) or MYCN
             non-amplified ganglioneuroblastoma verified by histology

          -  Patients must meet the specified criteria for one of the treatment groups defined
             below; genomic features include MYCN gene amplification, segmental chromosome
             aberrations (somatic copy number loss at 1p, 3p, 4p, or 11q or somatic copy number
             gain at 1q, 2p, or 17q) and deoxyribonucleic acid (DNA) index

               -  "Favorable" genomic features are defined by one or more whole-chromosome gains or
                  hyperdiploid tumor (DNA index > 1) in the absence of segmental chromosome
                  aberrations as defined above

               -  "Unfavorable" genomic features are defined by the presence of any segmental
                  chromosome aberration (somatic copy number loss at 1p, 3p, 4p, or 11q or somatic
                  copy number gain at 1q, 2p, or 17q) or diploid tumor (DNA index = 1); this
                  includes copy neutral loss of heterozygosity (LOH)

               -  Only patients with MYCN non-amplified tumors are eligible for this study

          -  Group A: patients < 12 months (< 365 days) of age with newly diagnosed INRG stage L1
             neuroblastoma/ganglioneuroblastoma who meet the following criteria:

               -  Greatest tumor diameter < 5 cm of adrenal or non-adrenal origin

               -  Patients with non-adrenal primaries are eligible, but must have positive uptake
                  on metaiodobenzylguanidine (MIBG) scan or elevated catecholamine metabolites
                  (urine or serum) to support the diagnosis of neuroblastoma

               -  No prior tumor resection or biopsy

          -  Group A will be further split into two subsets, which are mutually exclusive, for
             statistical purposes

               -  Group A1:

                    -  > 6 months and < 12 months of age with an adrenal primary tumor < 5 cm in
                       greatest diameter OR

                    -  Patients less than 6 months of age with an adrenal primary tumor > 3.1 and <
                       5 cm in greatest diameter OR

                    -  < 12 months of age with a non-adrenal primary site < 5 cm in greatest
                       diameter

               -  Group A2: =< 6 months of age with an adrenal primary site and tumor =< 3.1 cm in
                  greatest diameter.

          -  Group B: patients < 18 months (< 547 days) of age with newly diagnosed INRG stage L2
             neuroblastoma/ganglioneuroblastoma who meet the following criteria:

               -  No life threatening symptoms or no impending neurologic or other organ function
                  compromise (e.g. epidural or intraspinal tumors with existing or impending
                  neurologic impairment, periorbital or calvarial-based lesions with existing or
                  impending cranial nerve impairment, anatomic or mechanical compromise of critical
                  organ function by tumor [abdominal compartment syndrome, urinary obstruction,
                  etc.]); horner syndrome is not considered neurologic compromise

               -  No prior tumor resection, tumor biopsy ONLY

               -  Only patients with both favorable histology and favorable genomic features will
                  remain on study as part of Group B; the institution will be notified of
                  histologic and genomic results within 3 weeks of specimen submission on ANBL00B1
                  or APEC14B1

          -  Group C: patients < 18 months (< 547 days) of age with newly diagnosed INRG stage Ms
             neuroblastoma/ganglioneuroblastoma

          -  No prior radiotherapy or chemotherapy, with the exception of dexamethasone, which is
             allowed

          -  All patients and/or their parents or legal guardians must sign a written informed
             consent

          -  All institutional, Food and Drug Administration (FDA), and National Cancer Institute
             (NCI) requirements for human studies must be met

        Exclusion Criteria:

          -  Patients with MYCN amplified tumors are not eligible

          -  Group B and C patients who do not enroll on ANBL1232 within 4 weeks of definitive
             diagnostic procedure

          -  Group A and C patients, not required to undergo tumor biopsy, who do not enroll on
             ANBL1232 within 4 weeks of confirmatory imaging study

Maximum Eligible Age:	18 Months
Minimum Eligible Age:	N/A
Eligible Gender:	All
Healthy Volunteers:	No

Primary Outcome Measures

Measure:	Overall survival (OS) (Strata 1-4)
Time Frame:	3 years
Safety Issue:
Description:	OS time is calculated from date of enrollment until death, or until last contact if the patient is alive.

Details

Phase:	Phase 3
Primary Purpose:	Interventional
Overall Status:	Recruiting
Lead Sponsor:	Children's Oncology Group

Last Updated

August 25, 2021

Clinical Trials /

Response and Biology-Based Risk Factor-Guided Therapy in Treating Younger Patients With Non-high Risk Neuroblastoma